SPLASH BEVERAGE GROUP, INC.

Endovia Health Sciences (formerly Splash Beverage Group) announced an initial investment of $510,000 from C/M Capital Master Fund, LP, via a secured convertible promissory note. This note, with a principal of $576,271, is convertible into common stock and matures in September 2027. The funds are earmarked for the regulatory advancement, clinical development, and commercialization of CannEpil®. Additionally, the company reported selling 3,629,250 shares of common stock for $808,829.42 under a previously disclosed equity line of credit facility with the same investor.

Splash Beverage Group, Inc. announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026. Concurrently, the company will adopt a new ticker symbol "EDVA" and launch EndoviaSciences.com. This rebranding signifies a strategic transformation from a beverage business to a diversified cannabinoid health sciences platform, focusing on pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and innovative cannabinoid wellness products.

Splash Beverage Group, Inc. announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 24, 2026, along with a new ticker symbol "EDVA". This rebranding signifies a strategic shift from a beverage business to a diversified cannabinoid health sciences platform. The new entity will focus on commercializing pharmaceutical assets, advancing FDA-regulated human and veterinary therapeutics, and developing innovative cannabinoid wellness and beverage products.

Splash Beverage Group, Inc. has changed its corporate name to Endovia Health Sciences, Inc. The company initially filed a Certificate of Amendment on August 5, 2026, but subsequently filed a Certificate of Correction on August 6, 2026, to rectify a scrivener's error in the name change. The new name is effective in Nevada and will become effective on the NYSE American 10 days after a press release is issued.

Splash Beverage Group is undergoing a significant strategic shift, transitioning from its beverage business to focus on the cannabinoid and wellness markets, highlighted by the acquisition of exclusive worldwide rights to CannEpil®. This pivot comes amidst severe financial distress, including a going concern warning from auditors, recurring operating losses of $25.2 million in 2025, and ongoing NYSE American delisting risks due to equity non-compliance and low stock price. The company has filed an S-1 to register shares for an Equity Line of Credit, potentially raising up to $30.78 million to support its new direction and address financial needs, following a one-for-four reverse stock split.

Splash Beverage Group, Inc. announced a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product. The partnership will focus on companion-animal oncology and chronic pain management, with a goal to achieve FDA Center for Veterinary Medicine approval. Splash will retain ownership of all resulting data, intellectual property, and commercialization rights, while Lupvindol will lead the scientific and regulatory efforts.

Splash Beverage Group announced a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product. The program will initially target companion-animal oncology and chronic pain management, with Splash retaining ownership of all resulting data, intellectual property, and commercialization rights. Lupvindol will lead the scientific and regulatory activities, while Splash provides milestone-based funding and manages commercialization strategy. This collaboration aims to leverage the significant opportunity in the companion-animal health market, which includes a veterinary pain management market projected to reach $3.8 billion by 2030.

Splash Beverage Group entered a Development and Collaboration Agreement with Lupvindol Biosciences Ltd. to develop CannEpil®, a cannabinoid-based pharmaceutical product, as an Investigational Veterinary Product for companion-animal oncology and chronic pain management. Lupvindol will lead FDA regulatory activities and product development, while Splash will provide milestone funding totaling up to $1.115 million and an ongoing 4% royalty on net sales. The agreement aims for Conditional Approval of the new animal drug.

Splash Beverage Group, Inc. expanded its exclusive global license for CannEpil® with Argent BioPharma Limited to include veterinary therapeutic applications. This creates a second regulated pharmaceutical development platform, alongside its existing human program. The amendment grants Splash exclusive worldwide rights for CannEpil in veterinary medicine, with an initial focus on companion-animal oncology and chronic pain management, particularly for canine indications. The company will pay a 10% royalty on net revenues from veterinary applications and is finalizing a strategic joint venture for the veterinary development program.

Splash Beverage Group announced the expansion of its exclusive global license for CannEpil to include veterinary therapeutic applications, establishing a second pharmaceutical development platform. The company plans to initially evaluate CannEpil for companion-animal oncology and chronic pain management, with a focus on canine indications, and will seek U.S. regulatory approval via the FDA Center for Veterinary Medicine. This move positions CannEpil in significant and growing markets, with the global veterinary pain management market projected to reach $3.8 billion by 2030 and the veterinary oncology market estimated between $900 million and $1.7 billion. Splash is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.